Conference Coverage
Conference Coverage
11/10/2026
Brian McCurdy
A retrospective US analysis found AI-ECG and AI-Echo identified probable ATTR-CM in adults aged 50–95, with dual-positive screens associated with higher mortality.
11/10/2026
Conference Coverage
Conference Coverage
11/10/2026
Brian McCurdy
A retrospective study of 164 patients receiving disease-modifying therapy for ATTR-CM found genetic testing declined with age; 27.3% of tested patients had pathogenic TTR variants.
11/10/2026
Conference Coverage
Conference Coverage
11/10/2026
Brian McCurdy
An LLM chart-review study of 24,080 adults identified 218 untreated patients with suspected ATTR-CA and incomplete evaluations, most lacking a PYP order.
11/10/2026
Conference Coverage
Conference Coverage
11/10/2026
Ashton L. Stahl
A US multicenter study evaluated a 2-step pathway to reduce cardiac biopsy in patients with monoclonal protein abnormalities.
11/10/2026
Conference Coverage
Conference Coverage
11/09/2026
Ashton L. Stahl
In a retrospective heart failure cohort, sex-specific screening models outperformed the Mayo Simple Score in identifying transthyretin amyloidosis with cardiomyopathy (ATTR-CM), particularly among women—who...
11/09/2026
Conference Coverage
Conference Coverage
11/09/2026
Brian McCurdy
A probe-based immunoassay yielded an AUC of 0.819 for distinguishing ATTR-CM from cardiovascular controls, with lower TTR stability also observed in mildly symptomatic patients.
11/09/2026
Conference Coverage
Conference Coverage
11/09/2026
Brian McCurdy
A retrospective validation in 500 patients found 85.6% sensitivity and 74.8% specificity for an AI system integrating cardiac imaging, ECGs, and clinical notes to flag ATTR-CM risk.
11/09/2026
Research Summary
Research Summary
11/08/2026
Ashton L. Stahl
An exploratory ATTRibute-CM analysis assessed acoramidis effects on heart failure events over 30 months and mortality through 54 months.
11/08/2026
Conference Coverage
Conference Coverage
11/08/2026
Brian McCurdy
An ATTRibute-CM analysis examined NT-proBNP trajectories before and after cardiovascular hospitalization with acoramidis versus placebo.
11/08/2026
Conference Coverage
Conference Coverage
11/08/2026
Brian McCurdy
An ATTRibute-CM analysis evaluated first and recurrent cardiovascular hospitalizations and mortality with acoramidis vs placebo.
11/08/2026